Kezar Life Sciences (NASDAQ:KZR – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at HC Wainwright in a report released on Monday, Benzinga reports.
Kezar Life Sciences Price Performance
NASDAQ:KZR opened at $0.87 on Monday. Kezar Life Sciences has a 1-year low of $0.52 and a 1-year high of $1.14. The company has a 50-day moving average of $0.64 and a 200 day moving average of $0.69. The firm has a market cap of $63.34 million, a PE ratio of -0.62 and a beta of 0.21. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58.
Kezar Life Sciences (NASDAQ:KZR – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, research analysts anticipate that Kezar Life Sciences will post -1.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Kezar Life Sciences
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
Recommended Stories
- Five stocks we like better than Kezar Life Sciences
- What is Forex and How Does it Work?
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What Are Some of the Best Large-Cap Stocks to Buy?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Trading Halts Explained
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.